https://scholars.lib.ntu.edu.tw/handle/123456789/581912
標題: | Management of hepatitis C patients with decompensated liver disease | 作者: | Hsu C.-S. JIA-HORNG KAO |
關鍵字: | Antiviral agents; Direct acting antivirals; Genotype; Hepatitis C; Human; Liver failure | 公開日期: | 2016 | 出版社: | Taylor and Francis Ltd | 卷: | 10 | 期: | 6 | 起(迄)頁: | 679-688 | 來源出版物: | Expert Review of Gastroenterology and Hepatology | 摘要: | ABSTRACT: Little is known about the tolerance and effectiveness of novel oral direct acting antivirals (DAA) in hepatitis C patients with decompensated cirrhosis. To examine the studies relevant to the treatment of hepatitis C virus(HCV)-related decompensated liver disease, we performed computer–based searches for English articles between 1947 and August 2015. Fourteen articles including HCV patients with decompensated cirrhosis were reviewed. The combinations of ledipasvir(LDV)/sofosbuvir(SOF)/ribavirin(RBV) for 12 weeks, or daclatasvir/SOF/RBV for 12 weeks are safe and effective for HCV genotype 1 or 4 infection, and daclatasvir/SOF/RBV for 12 weeks or SOF/RBV for 24 weeks might be effective and safe for HCV genotype 2 or 3 infection. In conclusion, current evidence supports the use of all oral DAA regimens in HCV patients with decompensated cirrhosis. ? 2016 Informa UK Limited, trading as Taylor & Francis Group. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84958052073&doi=10.1586%2f17474124.2016.1143775&partnerID=40&md5=25f79a8f9cbd8f210c403e1fd1c351a3 https://scholars.lib.ntu.edu.tw/handle/123456789/581912 |
ISSN: | 1747-4124 | DOI: | 10.1586/17474124.2016.1143775 | SDG/關鍵字: | alanine aminotransferase; antivirus agent; asunaprevir; beclabuvir; bilirubin; creatinine; daclatasvir; dasabuvir plus ombitasvir plus paritaprevir plus ritonavir; interferon; ledipasvir; ombitasvir plus paritaprevir plus ritonavir; peginterferon; peginterferon alpha; peginterferon alpha2a; peginterferon alpha2b; placebo; ribavirin; simeprevir; sofosbuvir; antivirus agent; alanine aminotransferase blood level; anemia; antiviral therapy; arthralgia; asthenia; bilirubin blood level; creatinine blood level; decompensated liver cirrhosis; diarrhea; drug efficacy; drug safety; drug tolerability; drug withdrawal; fatigue; flu like syndrome; graft recipient; headache; hepatitis C; Hepatitis C virus genotype 1; Hepatitis C virus genotype 2; Hepatitis C virus genotype 3; Hepatitis C virus genotype 4; human; hypercholesterolemia; hypophosphatemia; liver transplantation; nausea; pruritus; Review; side effect; systematic review; treatment duration; treatment outcome; unspecified side effect; combination drug therapy; complication; drug effect; genetics; genotype; growth, development and aging; Hepacivirus; hepatitis C; liver cirrhosis; patient selection; recurrent disease; risk factor; virology; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Transplantation; Patient Selection; Recurrence; Risk Factors; Treatment Outcome |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。